{
    "root": "8d9390f9-1029-4990-a9a8-3e99a553a38c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "nebivolol",
    "value": "20250317",
    "ingredients": [
        {
            "name": "NEBIVOLOL HYDROCHLORIDE",
            "code": "JGS34J7L9I"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "FD&C BLUE NO. 2 ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "FD&C YELLOW NO. 6 ALUMINUM LAKE",
            "code": "GYP6Z2JR6Q"
        },
        {
            "name": "D&C RED NO. 27",
            "code": "2LRS185U6K"
        }
    ],
    "indications": "Nebivolol is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 5.5 )",
    "contraindications": "Can be taken with and without food. Individualize to the needs of the patient and monitor during up-titration. ( 2 ) • Hypertension: Most patients start at 5 mg once daily. Dose can be increased at 2-week intervals up to 40 mg. ( 2 )",
    "warningsAndPrecautions": "Nebivolol tablets are available as tablets for oral administration containing nebivolol hydrochloride equivalent to 2.5, 5, 10, and 20 mg of nebivolol.\n                  Nebivolol tablets have a mosaic appearance, are round, biconvex, uncoated, unscored, differentiated by color and are plain on one side and debossed with the number 53, 1354, 1355 or 1356 on the other side for the 2.5, 5, 10 and 20 mg tablets, respectively. Nebivolol tablets are supplied in the following strengths and package configurations:\n                  2.5 mg tablets are light blue colored with mosaic appearance, round, biconvex uncoated tablets, debossed with \"53\" on one side and plain on other side.\n                  Cartons of 30 tablets (10 tablets each blister pack x 3), NDC 0904-7225-04\n                  5 mg tablets are beige colored with mosaic appearance, round, biconvex uncoated tablets, debossed with \"1354\" on one side and plain on other side.\n                  Cartons of 30 tablets (10 tablets each blister pack x 3), NDC 0904-7189-04\n                  10 mg tablets are pinkish purple colored with mosaic appearance, round, biconvex uncoated tablets, debossed with \"1355\" on one side and plain on other side.\n                  Cartons of 30 tablets (10 tablets each blister pack x 3), NDC 0904-7190-04\n                  20 mg tablets are light blue colored with mosaic appearance, round, biconvex uncoated tablets, debossed with \"1356\" on one side and plain on other side.\n                  Cartons of 30 tablets (10 tablets each blister pack x 3), NDC 0904-7226-04\n                  \n                     Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F) [see USP for Controlled Room Temperature].\n                     \n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.",
    "adverseReactions": "Nebivolol is contraindicated in the following conditions:\n                  \n                     \n                        •\n                        Severe bradycardia\n                     \n                     \n                        •Heart block greater than first degree\n                     \n                        •Patients with cardiogenic shock\n                     \n                        •Decompensated cardiac failure\n                     \n                        •Sick sinus syndrome (unless a permanent pacemaker is in place)\n                     \n                        •Patients with severe hepatic impairment (Child-Pugh >B)\n                     \n                        •Patients who are hypersensitive to any component of this product."
}